Ascentage Pharma to Present Olverembatinib, APG-2449 and APG-5918 Preclinical Results at AACR
Ascentage Pharma will present four preclinical abstracts at the AACR Annual Meeting April 17–22, 2026 in San Diego, covering olverembatinib’s synergy with chemotherapy in endometrial carcinoma and with acalabrutinib in mantle cell lymphoma. Additional studies highlight APG-2449’s enhanced MAPK pathway blockade in BRAF V600E models and APG-5918’s epigenetic priming to boost topoisomerase I inhibitor efficacy in small‐cell lung cancer models.
1. Event Overview
Ascentage Pharma will present four preclinical study abstracts at the AACR Annual Meeting April 17–22, 2026 in San Diego, showcasing data from three novel pipeline candidates: olverembatinib (HQP1351), APG-2449 and APG-5918.
2. Olverembatinib Preclinical Data
Abstract #4583 demonstrates olverembatinib’s efficacy and synergy with chemotherapy in endometrial carcinoma models, while Abstract #5875 shows synergy with BTK inhibitor acalabrutinib in mantle cell lymphoma preclinical models.
3. APG-2449 Antitumor Enhancement
Abstract #1858 reports that FAK/ALK/ROS1 inhibitor APG-2449 increases antitumor activity when combined with MAPK pathway blockade in BRAF V600E-mutant tumor models, suggesting promising combination strategies.
4. APG-5918 Epigenetic Synergy
Abstract #4500 reveals that EED inhibitor APG-5918 synergizes with topoisomerase I inhibitors in small-cell lung cancer models by epigenetically priming tumor cells for enhanced chemosensitivity.